ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2019
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 342 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
342 citing papers in PubMed, 6 syntheses or guidelines pooled it, 645 citations in OpenAlex.
- Pooled it
- Efficacy and safety of imipenem/cilastatin/relebactam (IMI/CS/REL): a meta-analysis of randomized controlled clinical trials.BMC infectious diseases · 2025Pooled it
- Efficacy of treatment options for complicated urinary tract infections including acute pyelonephritis: a systematic literature review and network meta-analysis.Journal of comparative effectiveness research · 2025Pooled it
- Pooled it
- The prevalence of colistin resistance in clinical Stenotrophomonas maltophilia isolates worldwide: a systematic review and meta-analysis.BMC microbiology · 2023Pooled it
- The Status of Carbapenem Resistance in Cystic Fibrosis: A Systematic Review and Meta-Analysis.The Yale journal of biology and medicine · 2022Pooled it
- The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of People With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- Beyond Colonization: Dynamic Risk Stratification and Clinical Decision-Making for MDR Gram-Negative Infections in Critically Ill Patients.Biomedicines · 2026Review
- Eravacycline in Critically Ill Patients with Multidrug-Resistant Gram-Negative Infections: A Real-World Cohort Study.Journal of clinical medicine · 2026Article
- Performance evaluation of antimicrobial susceptibility testing methods for ceftazidime-avibactam and imipenem-relebactam against Klebsiella pneumoniae and Pseudomonas aeruginosa.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Evaluation of new expert rules for the detection and differentiation of carbapenemase-producing Enterobacterales within the French epidemiological context.Journal of clinical microbiology · 2026Article
- KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications 2026.Clinical and molecular hepatology · 2026Article
- Spatiotemporal genomic analysis and risk assessment of the plasmids carrying blaBMC microbiology · 2026Article
- Uropathogenic profiles and antibiotic resistance in gynecological cases: a microbial surveillance study from Northeast India.Scientific reports · 2026Article
- Carbapenemase-producing Enterobacterales infections: a real-world cohort study from a secondary hospital in Shanghai, China.BMC infectious diseases · 2026Article
- Evaluation of a Novel In Vitro Diagnostic Immunoassay for the Rapid Qualitative Detection of KPC, NDM, OXA-48-like, IMP and VIM Carbapenemases.Diagnostics (Basel, Switzerland) · 2026Article
- Deciphering the Genetic Mechanisms Driving Carbapenem Resistance: A Multicenter Study from Seven Egyptian Governorates Using Multiplex PCR and Whole Genome Sequencing.Current microbiology · 2026Article
- Evidence of cefiderocol-persistence inBiofilm · 2026Article
- Article
- Article
282 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance has become one of the greatest threats to public health, with rising resistance to carbapenems being a particular concern due to the lack of effective and safe alternative treatment options. Carbapenem-resistant gram-negative bacteria of clinical relevance include the Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii, and more recently, Stenotrophomonas maltophilia. Colistin and tigecycline have been used as first-line agents for the treatment of infections caused by these pathogens; however, there are uncertainties regarding their efficacy even when used in combination with other agents. More recently, several new agents with activity against certain carbapenem-resistant pathogens have been approved for clinical use or are reaching late-stage clinical development. They include ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, plazomicin, eravacycline, and cefiderocol. In addition, fosfomycin has been redeveloped in a new intravenous formulation. Data regarding the clinical efficacy of these new agents specific to infections caused by carbapenem-resistant pathogens are slowly emerging and appear to generally favor newer agents over previous best available therapy. As more treatment options become widely available for carbapenem-resistant gram-negative infections, the role of antimicrobial stewardship will become crucial in ensuring appropriate and rationale use of these new agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.